Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Tislelizumab With Oxaliplatin and Capecitabine in Microsatellite Stable, Locally Advanced Colon Cancer (NETSAC): A Single-arm, Single-center, Exploratory Phase II Clinical Study

NCT06124378 is registered in ClinicalTrials.gov with First Affiliated Hospital of Guangxi Medical University as lead sponsor.

NCT NCT06124378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06124378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Tislelizumab With Oxaliplatin and Capecitabine in Microsatellite Stable, Locally Advanced Colon Cancer (NETSAC): A Single-arm, Single-center, Exploratory Phase II Clinical Study
Lead sponsor
First Affiliated Hospital of Guangxi Medical University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 13, 2023
Completion date
November 30, 2026
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colonic neoplasms, immune checkpoint inhibitors, neoadjuvant therapy